Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at intervals following treatment with CAR-T cells improves CD 19 CAR-T cell persistence and reduces the incidence of leukemia relapse.

NCT Number	NCT03186118
Lead Sponsor	Seattle Children's Hospital
Conditions	CD 19+ Acute Leukemia
Enrollment	30 participants
Start Date	2017-08-04
Primary Completion	2021-09-13 (estimated)
Study Completion	2033-07 (estimated)
Updated on ClinicalTrials.gov	2026-06-05